- Net sales were €8,628 million, up 5.5% on a reported basis, up 3.9%(3) at CER and up 5.8% at CER/CS(4).
- Sanofi Genzyme sales up 21.8% due to strong launch performance of Dupixent®.
- Vaccines sales increased 24.7% mainly reflecting the recovery and growth of Pentaxim® in China and low basis for comparison.
- CHC sales up 1.1%, as U.S. growth more than offset lower sales in Europe impacted by non-strategic brand divestments.
- Primary Care GBU sales declined 10.4% at CER/CS mainly as a result of lower Diabetes sales.
- Emerging Markets sales(5) grew double-digits (up 10.0%) supported by higher Vaccines and Rare Disease sales.
2019 business EPS guidance revised upward
- Q2 2019 business net income increased 5.3% to €1,641 million and 4.9% at CER.
- Q2 2019 business EPS(1) up 4.8% at CER to €1.31.
- Q2 2019 IFRS EPS was -€0.07 (-115.5%) reflecting a €1.8 billion impairment charge mainly related to Eloctate®.
- Business EPS(1) in 2019 is now expected to grow approximately 5% at CER(6) barring unforeseen major adverse events. Applying the average July 2019 exchange rates, the currency impact on 2019 business EPS is estimated to be between 1% and 2%.
Key regulatory milestones achieved in R&D
- Isatuximab accepted for review by the FDA and EMA for approval in relapsed/refractory multiple myeloma.
- Libtayo® approved for advanced cutaneous squamous cell carcinoma in the EU.
- Dupixent® recommended by CHMP for atopic dermatitis in adolescents.
- Dupixent® approved in the U.S. for chronic rhinosinusitis with nasal polyposis.
- FDA accepted for review MenQuadfiTM, a meningococcal vaccine candidate.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.